Analysis on the clinical effect of apatinib mesylate tablet in the treatment of advanced non-small cell lung cancer
Objective To investigate the effect of lapatinib mesylate tablets in the patients with advanced non-small cell lung cancer. Methods A total of 55 patients with advanced non-small cell lung cancer who were given chemoth·erapy in our hospital from January 2015 to May 2017 were selected. Among them, 27 patients who were given paclitaxel combined with cisplatin for treatment were assigned to the conventional group. 28 patients who were given apatinib mesylate for treatment were assigned to the intervention group. The patient's therapeutic effect, related index changes, adverse reactions and quality of life were observed. Results ORR, DCR, total incidence rate of adverse reactions and quality of life in the intervention group were higher than those in the conventional group (P<0.05); the levels of CEA, VEGF and MMP-9 in the two groups after treatment were lower than those before treatment (P<0.05). Patients in the intervention group had lower levels of CEA, VEGF, and MMP-9 after treatment (P<0.05). Conclusion The clinical effect of lapatinib mesylate in the treatment of advanced non-small cell lung cancer is significant.